Multinational Pharma Giants and Tech Titans Accelerate Entry into AI Drug Discovery, Driving Full-Scale Industry Momentum

As we enter 2026, the development logic of the AI-driven drug discovery industry has undergone a fundamental shift. The sector is no longer preoccupied with whether to adopt AI in R&D, but has fully entered an intense competition focused on implementation speed, technological barriers, and industrial ecosystem.

 

Recently, Harbour BioMed and BioMap jointly announced the establishment of MegaStream TechBio, a new AI-driven drug discovery company targeting the global market. The new venture will deeply integrate BioMap’s xTrimo, a 268-billion-parameter multimodal large language model for life sciences, with Harbour BioMed’s high-quality global database of fully human antibodies accumulated over many years, achieving deep integration between large-scale computational models and biomedical industry data.

 

Securities analysts who have long tracked the biopharmaceutical sector commented that this collaboration breaks with conventional industry practices: in the past, the vast majority of collaborations between AI firms and pharmaceutical companies were limited to single-project outsourcing and technologyProcurementlevel, while the two parties directly establish an independent R&D joint venture to achieve an integrated layout of algorithms, computing power, biological data, and pipeline R&D, thereby upgrading the dimension of industry competition from single projects to a comprehensive R&D ecosystem barrier.

 

 

Throughout 2026, innovative pharmaceutical companies both in China and abroad, along with multinational giants, have significantly intensified their investments in AI-driven drug research and development, markedly accelerating the pace of their strategic deployments:

 

In January, CSPC and AstraZeneca established a strategic partnership to jointly develop long-acting innovative drugs, leveraging controlled-release drug delivery technologies and an AI-driven peptide discovery platform.

 

In March, Roche globally deployed an additional 2,176 high-performance GPUs to expand its dedicated AI R&D computational infrastructure; during the same period, Eli Lilly’s self-developed AI superfactory, LillyPod, officially commenced operations; Fosun Pharma continued to implement its “full-chain AI empowerment” strategy, promoting the penetration of artificial intelligence across all scenarios of drug research and development and industrialization.

 

Harbour BioMedPharmaceuticalsWang Jinsong, Founder, Chairman, and CEO, stated that the industry’s collective bet on AI is not a short-term trend, but rather reflects AI’s continuous delivery of tangible value in drug R&D. The role of AI has undergone a fundamental shift: from an auxiliary tool that previously accelerated isolated steps, it has evolved into the core underlying engine driving R&D design, pipeline decision-making, and clinical translation. The overall industry development trend is clear: AI is no longerEnterpriseRather than relying on external plug-in technologies, it is embedded within the R&D system as the core engine supporting innovation.

 

 

Not only traditional pharmaceutical companies, but global AI technology firms are also simultaneously intensifying their efforts in the drug discovery sector, creating a dual-track competitive landscape.

 

In April, OpenAI launched GPT-Rosalind, a large reasoning model specifically designed for drug discovery and translational medicine, with leading international pharmaceutical companies such as Amgen, Moderna, and the Allen Institute becoming its first batch of partner clients. In June, ByteDance spun off its AI-driven drug discovery business and initiated independent financing; all existing algorithm platforms, R&D pipelines, and core teams were transferred to the new entity. ByteDance retained controlling interest, while Volcano Engine continued to provide supporting computational power.

 

Currently, Chinese internet and technology enterprises such as ByteDance, Baidu, Huawei, and Tencent are all entering the AI drug discovery sector through methods including self-developed models, external collaborations, and independent entity operations, with computing power and algorithmic resources continuously being allocated to the biopharmaceutical field.

 

 

The fervor in industrial layout has simultaneously transmitted to the primary market, with investor confidence in the AI drug discovery sector showing a marked recovery. In late March, Huasen Pharmaceutical’s overseas AI R&D platform, Earendil Labs, secured a substantial $787 million in financing. Meanwhile, Deepwise, an AI healthcare service provider, raised a cumulative $150 million within just three months, underscoring sustained capital optimism regarding the commercial prospects of AI-driven pharmaceuticals.

 

 

Amid the industry’s rapid expansion, numerous deep-seated developmental shortcomings have gradually come to light.

 

First, AI currently covers only a few early-stage segments of drug R&D, while the lengthy processes of clinical development, formulation, and commercialization remain heavily reliant on traditional experimentation, resulting in limited overall empowerment. Second, the industry’s data silo problem remains difficult to resolve, with R&D data across different enterprises and institutionsStandardlack of standardization and interoperability constrains model training effectiveness; thirdly, there is a disconnect between algorithmic logic and the professional framework of life sciences, making cross-disciplinary integration challenging.

 

As the number of market participants continues to grow, the pharmaceutical industry has become increasingly mixed in quality. Industry practitioners have admitted that companies are continuously lowering their criteria for selecting AI partners, shifting from initially seeking technical collaborators capable of delivering breakthrough targets to merely screening for operationally stable and reliably deliverable partners.

 

 

The core evaluation criteria for investors in both the primary and secondary markets have returned to the fundamentals of the industry: whether AI-designed compounds can successfully navigate the clinical development process and ultimately achieve market approval and commercialization as new drugs.

 

Leading Chinese AI-driven drug discovery companies, including Insilico Medicine, XtalPi, and DTi Tech, have successively entered the capital markets. The market has begun to evaluate the value of AI technologies using real-world clinical and commercialization metrics from the pharmaceutical industry. A clear industry consensus has emerged: short-term capital influx and technological hype will eventually fade, and only companies capable of delivering new drugs that pass clinical validation and achieve commercial implementation will secure a firm footing in the long-term industry competition.